Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01142401 | Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | completed | Phase 2 | 118 | National Cancer Institute (NCI)NIH | 1 | Nov 27, 2023 | clinicaltrials |
| NCT00525759 | Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer(ANZAC) | completed | Phase 2 | 40 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER |
| 1 |
| Nov 24, 2023 |
| clinicaltrials |
| NCT03481998 | A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | completed | Phase 1 / Phase 2 | 104 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT02527434 | Study of Tremelimumab in Patients With Advanced Solid Tumors | completed | Phase 2 | 64 | AstraZenecaINDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT03054363 | Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer | completed | Phase 1 / Phase 2 | 42 | University of Colorado, DenverOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT00634634 | Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer | completed | Phase 1 / Phase 2 | 52 | Rutgers, The State University of New JerseyOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT03358017 | Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer(YAPPETIZER) | completed | Phase 2 | 54 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT01622868 | Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer | completed | Phase 2 | 143 | National Cancer Institute (NCI)NIH | 3 | Oct 17, 2023 | clinicaltrials |
| NCT04465097 | Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer(NeoTEE) | completed | Phase 2 | 30 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT00577122 | Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer | completed | Phase 2 | 30 | Indiana UniversityOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT02068092 | Olive Oil for High Risk Breast Cancer Prevention in Women | completed | Phase 2 / Phase 3 | 51 | The Methodist Hospital Research InstituteOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03121352 | Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer | completed | Phase 2 | 30 | Case Comprehensive Cancer CenterOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT00499083 | Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women) | completed | Phase 2 | 17 | University of NebraskaOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT01106898 | Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery | completed | Phase 2 | 112 | University of NebraskaOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT02101385 | Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer | completed | Phase 2 | 193 | Bryan Schneider, MDOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT00591851 | Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility | completed | Phase 2 | 70 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT00082641 | Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer | completed | Phase 1 / Phase 2 | 24 | University of NebraskaOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT04032080 | LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer | completed | Phase 2 | 10 | Baylor Research InstituteOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT03809988 | PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)(PALMIRA) | completed | Phase 2 | 198 | MedSIROTHER | 6 | Sep 7, 2023 | clinicaltrials |
| NCT01298713 | Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer | completed | Phase 2 | 111 | ARCAGY/ GINECO GROUPOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT02028364 | Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women(PEARL) | completed | Phase 2 | 55 | Jules Bordet InstituteOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT02066532 | Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer | completed | Phase 1 / Phase 2 | 32 | Dawn L. HershmanOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT02598557 | Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer | completed | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 2 | Aug 22, 2023 | clinicaltrials |
| NCT02614794 | A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer(HER2CLIMB) | completed | Phase 2 | 612 | Seagen Inc.INDUSTRY | 15 | Aug 14, 2023 | clinicaltrials |
| NCT02637024 | Trial of Radiation Fractionation Schedules for Once-a-Day Accelerated Partial Breast Irradiation(OPAR) | completed | Phase 2 | 280 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT03193853 | TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 12 | Joyce O'ShaughnessyOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT00255788 | Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer | completed | Phase 2 | 49 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00258375 | OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer | completed | Phase 2 | 15 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01138384 | Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 19 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01147484 | A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer(IND197) | completed | Phase 2 | 47 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01656538 | A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer | completed | Phase 2 | 81 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03018080 | Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer(PePPy) | completed | Phase 2 | 40 | Wake Forest University Health SciencesOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT00146562 | Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer | completed | Phase 2 | 135 | Harold J. Burstein, MD, PhDOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT03454529 | The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer | completed | Phase 2 | 24 | Michael SimonOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT03464942 | Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer(AZTEC) | completed | Phase 2 | 54 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT03735680 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | completed | Phase 2 | 30 | OncoNano Medicine, Inc.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT01124695 | Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer | completed | Phase 2 | 124 | ECOG-ACRIN Cancer Research GroupNETWORK | 3 | Jun 29, 2023 | clinicaltrials |
| NCT00244933 | Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer | completed | Phase 2 | 19 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00879086 | A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer | completed | Phase 2 | 104 | Eisai Inc.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01269346 | Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer | completed | Phase 2 | 52 | Eisai Inc.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01439282 | Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer | completed | Phase 2 | 77 | Eisai Inc.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05159778 | Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) | completed | Phase 2 | 26 | HiberCell, Inc.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00003236 | Chemotherapy in Treating Women With Previously Treated Metastatic Breast Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 18, 2023 | clinicaltrials |
| NCT02673398 | Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer | completed | Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT00579826 | Study of Breast Cancer Prevention by Letrozole in High Risk Women | completed | Phase 2 | 55 | Carol Fabian, MDOTHER | 1 | Jun 12, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Nov 27, 2023source: clinicaltrials